Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2008

View Archived Issues

Clinical benefit and recommended dose found in phase II TAS-108 study in breast cancer patients

Korea Research Institute of Chemical Technology patents agents for cerebral ischemia, etc.

New antiinfective agents reported in recent patent literature

Merck Frosst patents novel renin inhibitors for cardiovascular disorders

Phase III study shows Rituxan decreases progression of joint damage in early RA

Biofrontera reports positive phase III results with BF-200 ALA in actinic keratosis

FDA grants orphan drug designation to TransMolecular's 131I-TM-601 for melanoma

ArQule signs definitive license agreement with Daiichi Sankyo for selective c-Met inhibitor ARQ-197

Novozymes grants sanofi-aventis worldwide license for antimicrobial peptide Plectasin NZ-2114

Newron receives approval to initiate European and Asian phase IIb/III study of ralfinamide in NLBP

Takeda receives Japanese approval for additional indication of Actos in type 2 diabetes

PAION and Ergomed complete phase IIa study of CNS-5161 in opioid-refractory cancer pain

FDA accepts for review NeurogesX's NDA for NGX-4010 in post-herpetic neuralgia

RegeneRx gives update on release of clinical trial information

GSK and Theravance present positive phase IIb results for GW-642444 in COPD

Forest and Pierre Fabre sign collaboration agreement for F-2695 in the U.S. and Canada

Memory Pharmaceuticals reports positive phase I data for R-4996/MEM-63908

CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis

Novel peptide with antiinflammatory and cardioprotective activity discovered by Compugen

Inhibition of PDE4B receptor as a novel approach for the treatment of schizophrenia

SuperGen reports preclinical data for its panel of novel drugs for cancer

CHMP recommends new indication for Nycomed's TachoSil

CHMP recommends orphan drug status for Immunomedics' radiolabeled hPAM4

Takeda commences phase III cetilistat program in Japan for obesity

ArQule presents update on development of ARQ-621 and ARQ-761

FDA grants marketing authorization to Antisoma's oral fludarabine phosphate in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...